Biomarkers: Shaking Up--and Protecting--the World's Biggest Drug Market
Executive Summary
The ASTEROID trial for Crestor, showing that it's the first statin known to reduce arterial plaque, has shaken up the $20 billion statin business, showing how biomarkers-not clinical endpoints-can dramatically shift share in even well established markets. And while the news was largely bad for beleaguered Lipitor, the trial's reaffirmation of the importance of potency also shows why the coming generics won't significantly hurt the market leaders.
You may also be interested in...
Pfizer's Analyst Day: And Now, For Its Next Trick
Pfizer was vague in describing to analysts just how it would reduce costs by $4 billion per year by 2008. The FDA's announcement that it had asked Pfizer to remove the Cox-2 inhibitor Bextra from the market just days later complicates matters for the pharmaceutical giant. In any case, those hoping for a significant headcount reduction among Pfizer sales reps were surely disappointed.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.